Reduction of immunoreactivity against the C-Terminal region of the intracellular α-Synuclein by exogenous α-Synuclein aggregates: Possibility of conformational changes

Journal of Parkinson's Disease

Volumn 6, Issue 3, 2016, Pages 569-579

  Izumi, Yasuhiko ^a   Kondo, Naoto ^a   Takahashi, Ryosuke ^a   Akaike, Akinori ^a,b   Kume, Toshiaki ^a  

^a KYOTO UNIVERSITY   (Japan)

^b NAGOYA UNIVERSITY   (Japan)

Author keywords

conformational change; fibril; Parkinson disease; proteolysis; synuclein

Indexed keywords

ALPHA SYNUCLEIN; PROTEINASE INHIBITOR; SPERMINE; PROTEIN AGGREGATE; RECOMBINANT PROTEIN;

ACIDIFICATION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL LEVEL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYDROPHOBICITY; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; NEUROBLASTOMA CELL LINE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN DOMAIN; SH SY5Y CELL LINE; SURFACE CHARGE; WESTERN BLOTTING; CHEMISTRY; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; METABOLISM; TUMOR CELL LINE;

ALPHA-SYNUCLEIN; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; PROTEIN AGGREGATES; PROTEIN CONFORMATION; RECOMBINANT PROTEINS;

EID: 84983783155     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-160835     Document Type: Article

References (32)

1. Waxman EA, & Giasson BI (2009) Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta, 1792, 616-624.
2. Marques O, & Outeiro TF (2012) Alpha-synuclein: From secretion to dysfunction and death. Cell Death Dis, 3, e350.
3. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, & Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging, 24, 197-211.
4. Luk KC, Song C, O'Brien P, Stieber A, Branch JR, Brunden KR, Trojanowski JQ, & Lee VM (2009) Exogenous alpha-synuclein fibrils seed the formation of Lewy bodylike intracellular inclusions in cultured cells. Proc Natl Acad Sci USA, 106, 20051-20056.
5. Masuda-Suzukake M, Nonaka T, Hosokawa M, Oikawa T, Arai T, Akiyama H, Mann DM, & Hasegawa M (2013) Prion-like spreading of pathological, , α-synuclein in brain. Brain, 136, 1128-1138.
6. Kordower JH, Chu Y, Hauser RA, Freeman TB, & Olanow CW (2008) Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med, 14, 504-506.
7. Murray IV, Giasson BI, Quinn SM,KoppakaV, Axelsen PH, Ischiropoulos H, Trojanowski JQ, & Lee VM (2003) Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. Biochemistry, 42, 8530-8540.
8. Hoyer W, Cherny D, Subramaniam V, & Jovin TM (2004) Impact of the acidic C-terminal region comprising amino acids 109-140 on alpha-synuclein aggregation in vitro. Biochemistry, 43, 16233-16242.
9. Bertoncini CW, Jung YS, Fernandez CO, Hoyer W, Griesinger C, Jovin TM, & Zweckstetter M (2005) Release of long-range tertiary interactions potentiates aggregation of natively unstructured alpha-synuclein. Proc Natl Acad Sci USA, 102, 1430-1435.
10. Outeiro TF, Klucken J, Bercury K, Tetzlaff J, Putcha P, Oliveira LM, Quintas A, McLean PJ, & Hyman BT (2009) Dopamine-induced conformational changes in alpha-synuclein. PLoS One, 4, e6906.
11. Tsujimura A, Taguchi K,Watanabe Y, Tatebe H, Tokuda T, MizunoT, &TanakaM(2015)Lysosomal enzyme cathepsin B enhances the aggregate forming activity of exogenous, , α-synuclein fibrils. Neurobiol Dis, 73, 244-253.
12. Yamakawa K, Izumi Y, Takeuchi H, Yamamoto N, Kume T, Akaike A, Takahashi R, Shimohama S, & Sawada H (2010) Dopamine facilitates alpha-synuclein oligomeriza tion in human neuroblastoma SH-SY5Y cells. Biochem Biophys Res Commun, 391, 129-134.
13. Izumi Y, Yamamoto N, Matsushima S, Yamamoto T, Takada-Takatori Y, Akaike A, & Kume T (2015) Compensatory role of the Nrf2-ARE pathway against paraquat toxicity: Relevance of 26S proteasome activity. J Pharmacol Sci, 129, 150-159.
14. Schägger H, &von JagowG(1987)Tricine-sodium dodecyl sulfate polyacrylamide gel electrophoresis for the separation of proteins in the range from 1-100 kDalton. Anal Biochem, 166, 368-379.
15. Wittig I, Braun HP, &SchäggerH(2006) Blue native PAGE. Nat Protoc, 1, 418-428.
16. Perrin RJ, Payton JE, Barnett DH, Wraight CL,Woods WS, Ye L, & George JM (2003) Epitope mapping and specificity of the anti-Alpha-synuclein monoclonal antibody Syn-1 in mouse brain and cultured cell lines. Neurosci Lett, 349, 133-135.
17. Giasson BI, Jakes R, Goedert M, Duda JE, Leight S, Trojanowski JQ, & Lee VM (2000) A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res, 59, 528-533.
18. Oueslati A, Fournier M, & Lashuel HA (2010) Role of post-translational modifications in modulating the structure, function and toxicity of alpha-synuclein: Implications for Parkinson's disease pathogenesis and therapies. Prog Brain Res, 183, 115-145.
19. Sevlever D, Jiang P, & Yen SH (2008) Cathepsin D is the main lysosomal enzyme involved in the degradation of alpha-synuclein and generation of its carboxy-terminally truncated species. Biochemistry, 47, 9678-9687.
20. Fernández CO, Hoyer W, Zweckstetter M, Jares-Erijman EA, Subramaniam V, Griesinger C, & Jovin TM (2004) NMR of alpha-synuclein-polyamine complexes elucidates the mechanism and kinetics of induced aggregation. EMBO J, 23, 2039-2046.
21. McClendon S, Rospigliosi CC, & Eliezer D (2009) Charge neutralization and collapse of the C-terminal tail of alphasynuclein at low pH. Protein Sci, 18, 1531-1540.
22. Li W, West N, Colla E, Pletnikova O, Troncoso JC, Marsh L, Dawson TM, Jäkälä P, Hartmann T, Price DL, & Lee MK(2005) Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations. Proc Natl Acad Sci USA, 102, 2162-2167.
23. Izawa Y, Tateno H, Kameda H, Hirakawa K, Hato K, Yagi H, Hongo K, Mizobata T, & Kawata Y (2012) Role of C-terminal negative charges and tyrosine residues in fibril formation of, , α-synuclein. Brain Behav, 2, 595-605.
24. Antony T, Hoyer W, Cherny D, Heim G, Jovin TM, & Subramaniam V (2003) Cellular polyamines promote the aggregation of alpha-synuclein. J Biol Chem, 278, 3235-3240.
25. Sala-Rabanal M, Li DC, Dake GR, Kurata HT, Inyushin M, Skatchkov SN, & Nichols CG (2013) Polyamine transport by the polyspecific organic cation transporters OCT1, OCT2, and OCT3. Mol Pharm, 10, 1450-1458.
26. Glunde K, Düssmann H, Juretschke HP, & Leibfritz D (2002) Na(+)/H(+) exchange subtype 1 inhibition during extracellular acidification and hypoxia in glioma cells. J Neurochem, 80, 36-44.
27. Pacheco CR, Morales CN,Ramírez AE,Mũnoz FJ, Gallegos SS, Caviedes PA, Aguayo LG, & Opazo CM (2015) Extracellular, , α-synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane. J Neurochem, 132, 731-741.
28. Nielsen MS, Vorum H, Lindersson E, & Jensen PH (2001) Ca2+ binding to alpha-synuclein regulates ligand binding and oligomerization. J Biol Chem, 276, 22680-22684.
29. Nath S, Goodwin J, Engelborghs Y, & Pountney DL (2011) Raised calcium promotes, , α-synuclein aggregate formation. Mol Cell Neurosci, 46, 516-526.
30. Nonaka T,Watanabe ST, Iwatsubo T, &HasegawaM(2010) Seeded aggregation and toxicity of, , α-synuclein and tau: Cellular models of neurodegenerative diseases. J BiolChem, 285, 34885-34898.
31. Volpicelli-Daley LA, Luk KC, Patel TP, Tanik SA, Riddle DM, Stieber A, Meaney DF, Trojanowski JQ, & Lee VM (2011) Exogenous, , α-synuclein fibrils induce Lewy body pathology leading to synaptic dysfunction and neuron death. Neuron, 72, 57-71.
32. Luk KC, Kehm V, Carroll J, Zhang B, O'Brien P, Trojanowski JQ, & Lee VM (2012) Pathological, , α-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338, 949-953.